In the clinic, classic necroptosis inducers (TNF + cycloheximide + zVAD, TNF + 5Z-7-oxozeaenol + zVAD, and TNF + IAP inhibitors + zVAD) have been widely used for almost all common cancer types, including head and neck carcinoma, glioblastoma, colorectal cancer, hematopoietic neoplasm, hepatocarcinoma, lung cancer, breast cancer, and leukemia [90]. The gene discussed is TNF; the disease is breast carcinoma.